NCT03245190View on ClinicalTrials.gov

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 28, 2018

Primary Completion Date

November 1, 2019

Study Completion Date

November 1, 2019

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Chiauranib

50mg, orally once daily

Trial Locations (1)

200032

Zhongshan Hospital of Fudan University, Shanghai

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY